Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)
MWN-AI** Summary
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical-stage biopharmaceutical company focused on innovative therapies for liver and viral diseases, recently presented encouraging data at the Conference on Retroviruses and Opportunistic Infections (CROI) held from February 22 – 25, 2026, in Denver, Colorado. Their presentations highlighted significant findings from studies on two key compounds: pevifoscorvir sodium and ALG-097558.
Pevifoscorvir sodium, a potent CAM-E, is under investigation for treating chronic hepatitis B virus (HBV) infection. During a Phase 1 monotherapy study, positive results were showcased regarding viral suppression in subjects with chronic HBV infection. Led by presenter Stanley Wang, MD, this presentation provided compelling evidence supporting the potential of pevifoscorvir sodium as a first- or best-in-class therapeutic option for patients battling HBV.
In addition, ALG-097558, a ritonavir-free small molecule pan-coronavirus protease inhibitor, was discussed in context with its pharmacokinetics in participants with hepatic and renal impairment. Megan Fitzgerald, PhD, presented data on this compound, which is also progressing with federal funding from the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID).
Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and CEO of Aligos Therapeutics, expressed optimism about these developments. He emphasized the importance of advancing their COVID-19 program, alongside the promising data from the hepatitis B studies. The presentations can be accessed on Aligos' website for further details.
Aligos remains dedicated to developing best-in-class therapies to address high unmet medical needs in liver and viral diseases, supporting their mission with a robust research and development pipeline.
MWN-AI** Analysis
Aligos Therapeutics, Inc. (NASDAQ: ALGS) has presented promising data at the Conference on Retroviruses and Opportunistic Infections (CROI) that could significantly influence its market position and stock performance. The positive results pertaining to pevifoscorvir sodium for chronic hepatitis B virus (HBV) treatment and ALG-097558, a pan-coronavirus protease inhibitor, highlight Aligos's potential for innovation in the biopharmaceutical space.
The Phase 1 study of pevifoscorvir sodium highlighted high viral suppression in chronic HBV subjects, marking it as a potential first-/best-in-class treatment. Such data are vital, especially in a market increasingly focused on effective management of liver diseases. This could position Aligos favorably against competitors, potentially leading to heightened investor interest and favorable market sentiment. The company’s focus on significant therapeutic advancements aligns its narrative with current healthcare priorities, likely enhancing the attractiveness of its offerings to investors.
Additionally, ALG-097558’s results in patients with hepatic and renal impairment show the company’s commitment to developing treatments that cater to populations with complex medical needs, thereby expanding its target market. This unique selling proposition can attract investors looking for stocks with strong growth potential through diverse product pipelines.
From an investment perspective, market analysts should monitor Aligos's next moves closely, particularly as they look to progress towards further clinical trials and potential FDA approvals. Given the inherent risks in clinical-stage biotech, including regulatory hurdles and funding concerns, prospective investors should weigh these factors against the potential upside presented by positive clinical outcomes.
In summary, Aligos Therapeutics demonstrates promising advancements that may favorably impact its stock, but cautious optimism is warranted as the company navigates its clinical journey. Investors should keep a close watch on forthcoming data releases and regulatory developments to make informed decisions regarding ALGS.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from two presentations at the Conference on Retroviruses and Opportunistic Infections (CROI), being held February 22 – 25, 2026 in Denver, Colorado.
The pevifoscorvir sodium presentation highlights the Phase 1 monotherapy study of pevifoscorvir sodium, a potent CAM-E under development for the treatment of chronic hepatitis B virus (HBV) infection. Additionally, the ALG-097558 presentation showcases data from participants with hepatic and renal impairment. The ALG-097558 project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (HHS), under Contract No. 75N93023C00052.
“We are pleased to continue showcasing the best/first-in-class pevifoscorvir sodium data from the Phase 1 study in participants with chronic HBV infection,” said Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and CEO of Aligos Therapeutics. “Additionally, we continue to move our COVID program forward with grants from government agencies and are pleased to show some of this important clinical work at CROI this year.”
Details of the presentations are as follows:
Pevifoscorvir sodium: Potential first-/best-in-class small molecule CAM-E under investigation for chronic hepatitis B virus (HBV) infection
Poster #: 588
Title: High Viral Suppression in Chronic HBV Infection Subjects with Pevifoscorvir Sodium Monotherapy
Presenter: Stanley Wang, MD
Date/Time: February 23, 2026, 2:30pm – 4:00pm MST
Session: Beyond the C: Hepatitis D, B, and E
ALG-097558: Potential best-in-class ritonavir-free small molecule pan-coronavirus protease inhibitor
Poster #: 737
Title: Pharmacokinetics of ALG-097558, a Pan-Coronavirus 3CL-Pro Inhibitor, in Renal and Hepatic Impairment
Presenter: Megan Fitzgerald, PhD
Date/Time: February 25, 2026, 2:30pm – 4:00pm MST
Session: SARS-CoV-2 Therapy, Consequences, and Outcomes
The presentations can be found on the Posters & Presentations section of the Aligos website (www.aligos.com) after the live event.
About Aligos
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus (HBV) infection, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.
For more information, please visit www.aligos.com or follow us on LinkedIn or X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos’ capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 6, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Investor Contact
Aligos Therapeutics, Inc.
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com
Media Contact
Inizio Evoke
Jake Robison
Vice President
Jake.Robison@inizioevoke.com
FAQ**
What are the key takeaways from the positive data related to Aligos Therapeutics Inc. ALGS and their study on pevifoscorvir sodium for treating chronic HBV at the CROI 2026 conference?
How does the performance of ALG-097558 as a pan-coronavirus protease inhibitor impact the future direction of Aligos Therapeutics Inc. ALGS, especially in light of its applications in hepatic and renal impairment?
In what ways might the findings presented by Aligos Therapeutics Inc. ALGS at CROI 2026 influence investor confidence and the company’s stock performance moving forward?
What are the next steps for Aligos Therapeutics Inc. ALGS following the presentations at CROI 2026, particularly regarding regulatory approvals and advancing their clinical trials?
**MWN-AI FAQ is based on asking OpenAI questions about Aligos Therapeutics Inc. (NASDAQ: ALGS).
NASDAQ: ALGS
ALGS Trading
6.07% G/L:
$7.60 Last:
29,872 Volume:
$7.29 Open:
